Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Koenen-Bergmann

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Pharmaceutical Research|December 30, 2009
Population in vitro-in vivo correlation model for pramipexole slow-release oral formulationsElena Soto, Sebastian Haertter, Michael Koenen-Bergmann, et al.
Antimicrobial Agents and Chemotherapy|October 1, 2008
Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteersFenglei Huang, Michael Koenen-Bergmann, Thomas R Macgregor, et al.
British Journal of Clinical Pharmacology|January 11, 2013
Response to the letter by Dr Chin and co-workersSebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, et al.
British Journal of Clinical Pharmacology|February 22, 2012
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicinSebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, et al.
Respiratory Research|April 4, 2013
The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationaleRobert A Wise, Antonio Anzueto, Peter Calverley, et al.
The New England Journal of Medicine|September 3, 2013
Tiotropium Respimat inhaler and the risk of death in COPDRobert A Wise, Antonio Anzueto, Daniel Cotton, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Pharmaceutical Research|December 30, 2009
Population in vitro-in vivo correlation model for pramipexole slow-release oral formulationsElena Soto, Sebastian Haertter, Michael Koenen-Bergmann, et al.
Antimicrobial Agents and Chemotherapy|October 1, 2008
Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteersFenglei Huang, Michael Koenen-Bergmann, Thomas R Macgregor, et al.
British Journal of Clinical Pharmacology|January 11, 2013
Response to the letter by Dr Chin and co-workersSebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, et al.
British Journal of Clinical Pharmacology|February 22, 2012
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicinSebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, et al.
Respiratory Research|April 4, 2013
The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationaleRobert A Wise, Antonio Anzueto, Peter Calverley, et al.
The New England Journal of Medicine|September 3, 2013
Tiotropium Respimat inhaler and the risk of death in COPDRobert A Wise, Antonio Anzueto, Daniel Cotton, et al.
Pageof 1